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Introduction
The recent surge in the development of targeted kinase inhibitors as therapies for cancer was spurred from the success of imatinib (Gleevec ® , STI571) for the treatment of Philadelphia chromosome-positive chronic meylogenous leukemia. This drug, for the first time, showed that a small molecule could be designed to inhibit an oncogenic tyrosine kinase (BCR-ABL) that was responsible for inducing malignant transformation of a particular cell type. In spite of the fact that the majority of patients receiving imatinib respond to treatment at both the hematological and cytogenetic levels, relapse occurs in a subset of patients with chronic disease, and this number jumps significantly to nearly 100% in those patients whose disease is in the advanced stages (reviewed in 1).
Because of the frequency of mutations, it has become important to develop novel inhibitors that are active against imatinib resistant mutants of BCR-ABL. In response to this demand, two different promising compounds have recently been approved for the treatment of CML. These compounds known as BMS-354825 or Dasatinib, (2) and AMN107 or Nilotinib (3) were found to be inhibitory to nearly all imatinib-resistant forms of BCR-ABL with the exception of one mutation at position 315 where Threonine is replaced by Isoleucine (T315I). As this particular mutation is the most resistant to imatinib and emerges in the largest percentage of patients who develop resistance (reviewed in 4), there is an urgency to develop alternative compounds that are capable of inhibiting this particular (as well as other) amino acid substitution. A major goal of our team was to generate a potent inhibitor of BCR-ABL by targeting regions outside the ATP binding site of this enzyme as these compounds offer the potential to be unaffected by mutations that make CML cells resistant to imatinib.
Body Work accomplished by Dr. Reddy's Group
In last year's report we described the synthesis of 13 modifications of ON044580 on the benzoyl ring to enhance aqueous solubility and bioavailability of ON044580. Of these ON044690 and ON045260 were found to effectively inhibit wild-type BCR-ABL and T315I-BCR-ABL in cells and moderately inhibit their biochemical kinase activities in vitro. However, only ON045260 retained JAK-2 inhibitory activity comparable to the parent compound. This year's report describes bioavaiability studies with these modifications of ON044580, the development of ON045590 as an intermediate for lead optimization based on structure activity relationship (SAR) analysis and the simultaneous development of a nano-particle delivery system for ON044580 to overcome toxicity and solubility issues.
Caco-2 Cell Bioavailablity studies
Caco-2 cell permeability assays were performed on these modifications of ON044580 to test their bioavailability. Of the 13 compounds tested only 5 showed moderate to excellent Caco-2 cell permeability: ON044790, ON044870, ON045050, ON045230 and ON045240. However, these derivatives of ON044580 lost their cytotoxic and kinase inhibitory activities. Conversely, the modifications that retained biological activity, including ON045260, exhibited poor transport across the cells, indicating these modifications on the benzoyl ring did not improve the bioavailability of these molecules.
This work is summarized in Table 1 which shows cytotoxicity data against three cell lines (K562, Ba/F3:V617F-JAK2 and DU145) in addition to cell permeability for the compounds discussed. 
Modifications on the benzyl aromatic ring of ON044580
The above structure activity relationship (SAR) studies indicate that bioavailability of ON044580 can be improved by replacing one of the non-essential groups or atoms on one of its aromatic rings. Since the modifications on two of the three rings did not produce the optimized molecule, our informed strategy is to modify the groups that are present on the benzyl aromatic ring. In order to attach bioavailable groups (secondary and tertiary amines) it is necessary to make a intermediate with a tosyl moiety on the benzyl aromatic ring. We made this modification and called the resultant intermediate ON045590 whose structure is shown in Figure 1 . Having obtained the intermediate ON045590, we next assessed its activity in biological assays and found that the addition of a tosyl ester has not altered its cytotoxicity profile or its biological activity.
BCR-ABL kinase inhibitory activity of the intermediate ON045590
We tested the ability of ON045590 to inhibit the in vitro kinase activities of BCR-ABL proteins immunoprecipitated from mammalian cells. For these studies, cell lysates were prepared from K562 cells expressing the wild type BCR-ABL or 32D cells expressing the T315I mutant form of BCR-ABL. The immunoprecipitates were washed, re-suspended in kinase buffer and used for kinase assays using the GST-Abltide as a substrate.
Immunoprecipitates derived from 200 µg of total protein were used for a single assay reaction and were mixed with different concentrations of the inhibitor. The kinase assays were performed as described previously by us. Imatinib was used as a control in all of these assays.
As shown in Figure 2 , ON044580 potently inhibited the autophosphorylation of WT BCR-ABL and phosphorylation of GST-Abltide while the inhibitory activity of ON045590 was only slightly lower. As expected, imatinib inhibited both phosphorylations at 1µM.
We next compared the inhibitory activity of these compounds against the imatinib resistant T315I mutant form of BCR-ABL. Figure 3 shows that while imatinib failed to inhibit the mutant kinase at 10µM, ON044580 inhibited its autophosphorylation very potently. ON045590 by comparison was moderately active against the imatinib resistant form of BCR-ABL.
Imatinib inhibits only the WT form of BCR-ABL. In contrast ON045590 inhibits both WT and T315I mutant forms of BCR-ABL kinase, suggesting that mutations that affect the kinase inhibitory activity of imatinib do not affect the inhibitory activity of this modification of ON044580.
In vivo inhibition of BCR-ABL phosphorylation and signaling by ON045590.
To test the in vivo wild-type BCR-ABL inhibitory activity of ON04550 we treated K562 cells with increasing concentrations of the compounds for 2 hrs. Cells were washed and lysed in detergent containing buffer and the clarified lysates subjected to SDS-PAGE followed by western blotting to detect the phosphorylation status of BCR-ABL and STAT-3. The results of this study, presented in Figure 4 , show that ON045590 is able to inhibit the phosphorylation of BCR-ABL and its downstream target STAT-3 in a concentration dependent manner.
In vitro tumor cell killing activity of ON045590
We next examined the ability of ON045590 to inhibit the proliferation of BCR-ABL positive myeloid leukemias. To this end we studied the ability of this compound to inhibit the growth of imatinib sensitive K562 cells which express WT BCR-ABL kinase and used the human prostrate cancer cell line DU145 as a comparison. The results presented in Figure 5 show ON045590 is an effective inducer of tumor cell death exhibiting GI 50 values of 4 µM for K562 cells and 1.5 μM for DU145 cells. This seems to be a reversal of trend from ON044580 which showed better activity against K562 as compared to DU145 cells.
JAK2 inhibitory activity of ON compounds
ON044580 is a dual inhibitor of BCR-ABL and JAK-2 kinases. Having confirmed that ON045590 inhibits BCR-ABL we were keen to learn of its ability to inhibit JAK-2. To test the JAK2 inhibitory activity of ON045590, we used the recombinant constitutively activated V617F mutant form of this protein produced in insect cells (which is commercially available). As shown in Figure 6 we found that ON045590 shows potent JAK-2 kinase inhibitory activity easily comparable to the parent molecule (ON044580).
Growth inhibition of V617F-JAK2 expressing cells.
To determine whether ON045590 inhibits the proliferation of V617F-JAK2-positive leukemic cells as potently as ON044580, we studied its effect on the growth and viability of Ba/F3:V617F-JAK2 cells which were transfected with an expression vector that encodes the mutant JAK2. The results of this study, presented in Figure 7 show that ON045590 can readily inhibit the proliferation and induce apoptosis of all this cell line with a GI 50 value of 380 nM which matches 350 nM of ON044580 we reported earlier.
Hence, ON045590 was found by us to be a suitable intermediate of ON044580 retaining its dual kinase inhibitory and cytotoxic properties. We are currently introducing groups containing secondary and tertiary amines with the hope that the resulting molecule will be more bioavailable than ON044580 and still retain its biological activities.
Nanoparticle delivery of ON044580
In our attempt to assess the efficacy of ON044580 in tumor xenografts models we first attempted to test its toxicity in mice. We found ON044580 dissolved in DMSO to be toxic by tail vein injection and subcutaneous administration at doses of 25mg/kg body weight. This toxicity appears to be partially to be due to DMSO which was used as a solvent. In addition, ON044580 was found to be very insoluble and biologically unavailable. Our attempts at modifying the available side groups of ON044580 invariably led to decrease in its potent kinase inhibitory and/or cytotoxic activities. Hence, we decided to use targeted nanoparticles as a delivery system for administration of ON044580 and its bioactive analogs. We chose to utilize the transferrin-transferrin receptor system to encapsulate the drug because of the biological advantages that this system offers.
Metabolically active cells demand high amounts of iron. Rapidly proliferating malignant cells [5] and metabolically active brain cells [6] express higher number of transferrin receptors to facilitate higher iron transport. The use of apotransferrin, transferrin and transferrin receptor antibodies (OX-26) as carriers of drug for targeted delivery to transferrin receptor expressing cells is extensively studied [7] .
To reduce the entry of drug into non target cells, several target specific technologies have been developed during the last few years and implemented. Most of these technologies invoke the use of polymeric materials (PEG, PLGA) [8] and proteins (chitins, albumin).
These materials though excellent carriers of drug, lack target specificity [9] . Thus target specific ligands like transferrin, antibodies, carbohydrates, signal peptides are widely studied for guiding these delivery systems to specific cells and tissues [10] . We reports a target directed nanoparticle drug delivery system comprising of drug loaded transferrin nanoparticles.
Method of preparation of nanoparticles
The schematic below (Figure 8 ) details the method for preparation of transferring nanoparticles containing ON044580 and Doxorubicin as a control.
Size of nanoparticles
The size of the particles was measured by the Beckmann Delsa Nano instrument. The average diameter of drug loaded transferrin nanoparticle was found to be 307nm with a standard deviation of 122nm using the zeta potential sizing method. As is evident from the chart below, the majority of nanoparticles were well below 500nm in diameter.
Estimation of drug encapsulation in nanoparticles
In order to be used in biological assays it is imperative that the concentration of drug within the nanoparticle preparation be determined. To that end, 100 µL of the drugloaded nanoparticles were centrifuged at 4000 x g and the supernatant discarded. The pellet was dispersed in 300 µL acetonitrile and vortexed for 10 minute to release the drug from the nanoparticles. The mixture was centrifuged at 12,000 x g for 10 minutes and the supernatant was analyzed. for the drug by high pressure liquid chromatography (HPLC) method using the known concentrations of the drug as standard references.
ON44580 Standards:
HPLC analysis of ON44580 standards gave a peak of height of 660 mAU and 94 % area for 1 mg/ml drug concentration.
ON44580 released from transferring nanoparticles:
HPLC analysis of ON044580 released from nanoparticles shows a height of 823 mAU and a 90 % area under the curve. This is equivalent to 1.22 mg/ml. The original sample was diluted three-fold in acetonitrile, hence the preparation contains 3.66 mg/ml of ON044580. A total of 8 mg ON044580 was used in the preparation of the nanoparticles.
This translates to approximately 45% encapsulation efficiency. Given the molecular weight of ON044580 (514 daltons) the molar concentration of ON044580 in this preparation is estimated to be 7.12 mM.
Doxorubicin nanoparticles
Similar protocols were employed to make and assess doxorubicin (a known chemotherapeutic with potent anticancer activity) encapsulation in transferring nanoparticles. We found that our preparation of doxorubicin had an encapsulation efficiency of 40% and a molar concentration of 40 µM.
ON044580 loaded transferrin nanoparticles are non-toxic to mice
Having prepared drug containing transferring nanoparticles we tested their toxicity profiles in mice. Female CD-1 mice (25 grams) were injected (IP injections) with a sublethal (24 mg/kg) and lethal dose (64 mg/kg) of ON044580 formulated as nanoparticles. The mice were observed for over 2 weeks with no signs of toxicity or weight loss. However, the injection of these nanoparticles was difficult due to the "stickiness" of the preparations. This could well be due to the size of the nanoparticles (hundereds of nanometer diameter). We are currently working on making finer nanoparticle preparations for greater ease of administration.
Cytotoxicity of ON044580-transferrin nanoparticles
After determining the safety of the nanoparticles in mice we tested their ability to be endocytosed by tumor cells and cause growth inhibition. We carried out cytotoxicity analysis using ON044580 and doxorubicin containing transferring nanoparticles on two cell lines: 32D:p210-T315I cells overexpressing the imatinib resistant mutant of BCR-ABL and Ba/F3:V617F-JAK2 cells that ectopically overexpress the activated JAK-2 mutant.
As can be seen in Figure 9 the nanoparticles of both drugs were excellent inhibitors of tumor cell growth. Against 32D:p210-T315I cells both doxorubicin and ON044580 had GI 50 values of 25µM. However, as can be seen in Figure 10 range.
We will test the efficacy of these ON044580 nanoparticles and/or those of its bioactive analogs with better pharmacokinetic properties to treat mouse models of chronic myelogenous leukemia (CML) and myeloproliferative disorders (MPD).
Key research accomplishments: Using TGAY1 we have learned that Jak2 is the therapeutic target in CML and that TGAY1 is a potent Jak2 inhibitor, which may be useful for CML therapy. In the current study we have presented the supporting data regarding the mode of action of On044580 and TGAY1 in Bcr-Abl+ cells.
Body

ON-044580 is a Jak2 inhibitor:
We observed initially from year 1 study that the compound can induce apoptosis in major IM-resistant cells and blast crisis cells from CML patients (4-6, 7). We suspected that these potent inhibitory effects may be due to inhibition of Jak2 in the Bcr-Abl driven signaling pathway. To establish our hypothesis that Jak2 is a critical regulator of Bcr-Abl signaling, we used a specific Jak2 inhibitor (8) (TargeGen Inc. TG101209, TGAY1) to compare and contrast the Jak2 inhibitory effects with those of ON-044580 in Bcr-Abl+ cells. We concluded that several of the effects that we observed in Bcr-Abl + cells treated with ON-044580 are due to Jak2 inhibitory effects. Let us explore the basis of our hypothesis step by step. After 60 min Bcr-Abl level was reduced (Fig 1) . In order to compare the property with Jak2 inhibitors, we incubated Bcr-Abl+ cells with TGAY1 under identical conditions and we observed that Bcr-Abl was reduced by Jak2 inhibition (Fig 3) . We explored the basis of Bcr-Abl disappearance. Bcr-Abl is phosphorylated on tyrosine 177 (9) . Note that after Jak2 inhibition, total BcrAbl protein levels also rapidly disappear but at a slower rate than pTyr 177/pTyr 360 and total pTyr residues of Bcr-Abl (Fig. 3) . Both these tyrosine residues have consensus sequences for Jak2 dependent phosphorylation (YxxV/I/L/F) (10). This event leads to binding of Bcr-Abl to Grb2 and activation of the SOS-Ras pathway (4), and activation of the PI-3 kinase through the Grb2-Gab2 pathway. We anticipated that instability of BcrAbl may be due to inhibition of pTyr177. We surprisingly demonstrated that indeed, pTyr177 was reduced in Bcr-Abl+ cells in a time dependent manner when incubated BcrAbl+ cells with On044580 (Fig. 2) . We also observed the similar effects in TGAY1 treated cells (Fig. 3 ). Total pBcr-Abl level was also reduced in Jak2 inhibitor treated cells ( Fig.3-5 ). In an in vitro kinase assay SET was used to immunoprecipitate Bcr-Abl and pJak2. We demonstrated that addition of Jak2 inhibitors to the kinase assay reduced pJak2 level, pTyr177 and but not the total Bcr-Abl level (Fig. 6) . These results indicate that inhibition of Jak2 for just 15 min caused removal of phosphates from tyrosine 177, suggesting that active Jak2 is continuously required to phosphorylate these two sites, and possibly others sites in Bcr-Abl. Similarly, TGAY1 also inhibited phosphorylation of Tyr 177 of Bcr-Abl under these conditions (Fig.3 ) and in kinase assays conducted on anti-SET IPs (Fig. 6 ).
Stability of Bcr-Abl depends on
imatinib mesylate (IM) did not rapidly inhibit tyrosine phosphorylation of BcrAbl on Tyr 177, nor did IM cause rapid loss of Bcr-Abl from the cell lysate (Fig. 7) .
However, treatment of Bcr-Abl+ cells with IM for much longer times decreases Bcr-Abl protein levels ( Fig. 8) but at a much later time (more than 6 h).
On044580 disrupted Bcr-Abl driven signaling pathways: Autophosphorylation of
Bcr-Abl at Tyr 177 makes a docking site for scaffolding protein Grb2 through its SH2
domain. This leads to phosphorylation of Gab2 due to a Jak2/Lyn kinase pathway (unpublished) and recruitment of Gab2 to Grb2 through its SH3 domain. One site of
Gab2 is bound to a regulatory subunit of PI3 kinase through which Akt is eventually phosphorylated (11, 12) . Another site of SH3 domain of Grb2 is connected to SOS molecule through which Ras is connected with Ras -Raf-Erk pathway (15) . These pathways are critical for cell proliferation, survival and transformation. Thus, treatment of Bcr-Abl+ cells with On044580 is expected to disrupt both of these signaling pathways through reduction pTyr 177 of Bcr-Abl (our hypothesis). In the following experiments we have presented evidence in support of this hypothesis.
(a) Ras-GTP pathway is disrupted by On044580-We have measured Ras-GTP levels after treatment of Bcr-Abl+ cells with On044580 in serum starved cells (8h). After that we analyzed Ras-GTP following the manufacturer protocol following their kit (MilliporeUpstate Company). Figure 9 shows that with respect to untreated cells, Ras-GTP (15) level was reduced within 60 min, indicating that Ras pathway is being strongly inhibited by On044580 (Fig.9) .. (Fig.10) . To confirm that this property of disruption of Bcr-Abl signaling pathways was contributed by Jak2 inhibition, we treated the cells with TGAY1 and under identical conditions and we measured pSTAT5 and pGab2 ( Fig. 11 and 12 ). We observed the pSTAT5 level was reduced in On044580 treated cells indicating that Jak2 kinase inhibitory effect of On044580 also disrupted these additional Bcr-Abl signaling pathways. We believe these effects of On044580 on pTyr STAT5 are due to Jak2 inhibition, which causes the severe reduction of Bcr-Abl. Thus, Bcr-Abl is not available to activate STAT5. The effects of On044580 on pShc are more complex, and needs further experimentation. We suggest that Jak2 also phosphorylates the YvnV sequence of Shc, and that Jak2 inhibition then prevents its phosphorylation at this Tyr site, thus The kinase assay of Jak2 was done as described (19) in presence of either Jak2 inhibitor TGAY1 or or Abl kinase inhibitor Imatinib. We observed that the Jak2 inhibitor strongly inhibited catalytic activity of the enzyme whereas Imatinib failed to inhibit ( Fig.13 and 14) . Under identical conditions we measured Jak2 kinase activity using recombinant Jak2 kinase and same peptide substrate in presence and absence of On044580. We observed that Jak2 kinase activity was reduced in presence of Ono44580 in a dose-response manner. It suggests that Jak2 inhibitory effects of Onconova compound is very inhibitory but is slightly less potent than TGAY1. (Fig. 17) . That activated Jak2 is critical for phosphorylation of Tyr 177 is confirmed by the relative lack of Jak2 activation in cells lacking the IL-3 receptor but expressing Bcr-Abl (Fig. 17) . A model depicting the involvement of IL-3 receptor for the activation of pJak2 is presented in Fig.18 . Work is in progress to determine the effects of pJak2 activation and pTyr177 Bcr-Abl expression in presence of On044580 in the Bcr-Abl this system (18). ( Fig.19A and B ) . which can induce apoptosis of Bcr-Abl+ IM sensitive and resist ant cells (Fig 20A and B and Fig. 21A and B) . Of interest we showed that viability of peripheral mononuclear cells derived from three normal persons was not affected by either TGAY1 or by Ursolic acid compared to untreated cells (Fig.22) (2) Jak2 controls phosphorylation of Ty177 of Bcr-Abl;, therefore, SOS-Ras-RAF pathway and PI3 kinase-Akt pathways are under control of Jak2in Bcr-Abl+ cells (3) Jak2 Phosphorylates Tyr705 STAT3 (4) Jak2 regulates NF-kB activation (5) Jak2 regulates HSP90 synthesis (6) We found that Jak2 has a critical role in the formation and stabilization of Bcr-AblJak2-HSP90 network complex. 
Induction of apoptosis in IM-
